consolidated gross profit in 3Q2017 was THB 795.27 million, improved by THB 46.82 million or 6.26% up from 3Q2016. The consolidated gross profit margin contributed of 18.08% in 3Q2017, increased from 16.97% in
full-year 2019 was THB 3,624.2mn. Of which, THB 499.0mn and THB 3,055.6mn, respectively, were from sales of real estate (transfer ownership to buyers) • Gross profit from sales of real estate in 4Q
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
11.86% Finance cost 19.72 18.41 (1.31) (6.64%) Income tax expenses 17.98 22.21 4.23 23.53% Net profit 70.57 80.50 9.93 14.07% Net profit ratio (ROS) 20.41% 18.98% Earnings per share (Baht) 0.13 0.15 0.02
Profit (Loss) (16.93) (2.20) 14.73 669.55 Earnings per share (Baht per share) (0.0032) (0.0005) 0.0027 540.00 Net Profit (Loss) The Company and subsidiaries (Consolidated) realized net loss of 16.93
: Overall Financial Performance Unit: million baht Jan-Jun 2018 % Jan-Jun 2019 % Change % YoY Revenue 254.34 100.0% 273.96 100.0% 19.62 7.7% Cost 144.42 56.8% 147.42 53.8% 3.00 2.1% Gross Profit 109.92 43.2
year which posted total net profit Baht 495 million. Total revenue from sales and services amounted to Baht 3,398 million, decreased by Baht 4,750 million or 58% YoY. Separate financial statement, the
administrative expenses 15,131 18,982 (20.29) Net profit (loss) 10,477 126,984 (91.75) Sales revenue increased by 6.83% mostly from orders from overseas customers, due to the Covid-19 pandemic during Q2 which
-21.785 -8.91 Profit (Loss) from Exchange Rate 4.09 4.61 0.52 12.71 1.19 0.48 0.35 -0.13 -27.08 -0.84 -70.59 Other Revenue 5.51 6.63 1.12 20.33 2.13 1.18 1.32 0.14 11.86 -0.81 -38.03 Gain from buying at a